Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same

1. A method for treatment of acute onset nausea and/or emesis in a mammal comprising administering to the mammal a pharmaceutical formulation comprising a crystalline salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one, and a pharmaceutically acceptable excipient.

2. The method of claim 1 , wherein the nausea and/or emesis arises from chemotherapy, radiation therapy, or during a post-operative recovery period.

3. The method of claim 1 , wherein said formulation comprises 5, 10, 25, 50, 100 or 200 mg of the crystalline hydrochloride monohydrate salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one.

4. The method of claim 1 , wherein said formulation is incorporated into an oral dosage form.

5. A method for the treatment of acute onset emesis and/or acute onset nausea along with chemotherapy by administering a combination comprising a pharmaceutical formulation comprising a crystalline salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one and a chemotherapeutic agent to a patient in need of chemotherapy.

6. The method of claim 5 , wherein said formulation is administered contemporaneously or simultaneously with the chemotherapeutic agent to the patient in need of chemotherapy, thereby providing therapy for acute onset emesis and/or acute onset nausea along with chemotherapy.

7. The method of claim 6 , wherein the formulation is administered contemporaneously with the chemotherapeutic agent.

8. The method of claim 7 , wherein the formulation is administered contemporaneously with the chemotherapeutic agent such that the formulation is administered before administration of the chemotherapeutic agent.

9. The method of claim 7 , wherein the formulation is administered contemporaneously with the chemotherapeutic agent such that the formulation is administered during administration of the chemotherapeutic agent.

10. The method of claim 7 , wherein the formulation is administered contemporaneously with the chemotherapeutic agent such that the formulation is administered after administration of the chemotherapeutic agent.

11. The method of claim 1 , wherein the salt is a hydrochloride salt.

12. The method of claim 11 , wherein the salt is a monohydrate hydrochloride.

13. The method of claim 1 , wherein the pharmaceutically acceptable excipient is selected from at least one of the group consisting of lactose, microcrystalline cellulose, croscarmellose sodium, pregelatinized starch, and magnesium stearate.

14. The method of claim 1 , wherein the formulation is a granular formulation.

15. The method of claim 1 , wherein the pharmaceutical formulation comprises 5-200 mg of the crystalline salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one per dosage form.

16. The method of claim 1 , wherein the pharmaceutical formulation contains 200 mg of the crystalline salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one.

17. A method of providing therapy to a patient in need of treatment thereof for acute onset emesis and/or acute onset nausea along with chemotherapy by administering a combination comprising a pharmaceutical formulation comprising a crystalline hydrochloride monohydrate salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one, a corticosteroid and/or a 5HT3 receptor antagonist and a chemotherapeutic agent to a patient in need of chemotherapy and treatment for chemotherapy-induced nausea and emesis.

18. The method of claim 17 , wherein the corticosteroid is selected from dexamethasone and the 5HT3 antagonist is selected from the group consisting of ondansetron, granisetron, palonosetron, dolasetron or tropisetron.

19. The method of claim 17 , wherein the pharmaceutical formulation comprises 5 to 200 mg of the crystalline hydrochloride monohydrate salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one.

20. The method of claim 19 , wherein the pharmacokinetic (PK) profile of said 5-200 mg crystalline hydrochloride monohydrate salt in a patient in need of treatment thereof under single dose rising rate study conditions is: Cmax (ng/mL) 27.3 to 944 ng/mL; Tmax 2-4 hrs; AUC 931 to 148000 ng/hr/mL and Half Life T ½ (hours) 169-183 hrs.

21. A method of providing therapy to a patient in need of treatment for acute onset emesis and/or acute onset nausea comprising administration of an oral dosage form of a pharmaceutical formulation comprising 5-200 mg of a crystalline hydrochloride monohydrate salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one.

22. The method of claim 21 wherein the oral dosage form is a tablet or a capsule.

23. The method of claim 22 wherein the oral dosage form is a tablet.

24. The method of claim 23 , wherein the tablet comprises 200 mg of the crystalline hydrochloride monohydrate salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one.